ZVRA - Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in
ZVRA - Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union - Click For Release
Story updates
11:30:54 AM UTC
SquawkNews
ZVRA Zevra Therapeutics provides update on regulatory submission for arimoclomol for the treatment of niemann-pick disease type C (npc) in the European union Zevra Therapeutics - chmp adopts negative opinion on arimoclomol maa for niemann-pick disease type C - To request Re-examination of chmp opinion on arimoclomol
ZVRA Zevra Therapeutics provides update on regulatory submission for arimoclomol for the treatment of niemann-pick disease type C (npc) in the European union Zevra Therapeutics - chmp adopts negative opinion on arimoclomol maa for niemann-pick disease type C - To request Re-examination of chmp opinion on arimoclomol